Capricor Therapeutics (NASDAQ:CAPR) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Get Rating) in a research note issued to investors on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Capricor Therapeutics Trading Down 4.7 %

CAPR stock opened at $4.34 on Thursday. Capricor Therapeutics has a 52 week low of $2.81 and a 52 week high of $6.58. The firm has a 50 day moving average of $4.35 and a 200 day moving average of $4.76.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Charles Schwab Investment Management Inc. acquired a new stake in Capricor Therapeutics during the 1st quarter valued at approximately $51,000. Renaissance Technologies LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter valued at approximately $61,000. HighTower Advisors LLC lifted its stake in Capricor Therapeutics by 17.8% during the 4th quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 3,001 shares during the period. UBS Group AG lifted its stake in Capricor Therapeutics by 326.0% during the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 22,462 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the 4th quarter valued at approximately $109,000. 11.06% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.